Cargando…

Presenilins as Drug Targets for Alzheimer’s Disease—Recent Insights from Cell Biology and Electrophysiology as Novel Opportunities in Drug Development

A major cause underlying familial Alzheimer’s disease (AD) are mutations in presenilin proteins, presenilin 1 (PS1) and presenilin 2 (PS2). Presenilins are components of the γ-secretase complex which, when mutated, can affect amyloid precursor protein (APP) processing to toxic forms of amyloid beta...

Descripción completa

Detalles Bibliográficos
Autores principales: Duncan, R. Scott, Song, Bob, Koulen, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032171/
https://www.ncbi.nlm.nih.gov/pubmed/29857474
http://dx.doi.org/10.3390/ijms19061621
_version_ 1783337452183748608
author Duncan, R. Scott
Song, Bob
Koulen, Peter
author_facet Duncan, R. Scott
Song, Bob
Koulen, Peter
author_sort Duncan, R. Scott
collection PubMed
description A major cause underlying familial Alzheimer’s disease (AD) are mutations in presenilin proteins, presenilin 1 (PS1) and presenilin 2 (PS2). Presenilins are components of the γ-secretase complex which, when mutated, can affect amyloid precursor protein (APP) processing to toxic forms of amyloid beta (Aβ). Consequently, presenilins have been the target of numerous and varied research efforts to develop therapeutic strategies for AD. The presenilin 1 gene harbors the largest number of AD-causing mutations resulting in the late onset familial form of AD. As a result, the majority of efforts for drug development focused on PS1 and Aβ. Soon after the discovery of the major involvement of PS1 and PS2 in γ-secretase activity, it became clear that neuronal signaling, particularly calcium ion (Ca(2+)) signaling, is regulated by presenilins and impacted by mutations in presenilin genes. Intracellular Ca(2+) signaling not only controls the activity of neurons, but also gene expression patterns, structural functionality of the cytoskeleton, synaptic connectivity and viability. Here, we will briefly review the role of presenilins in γ-secretase activity, then focus on the regulation of Ca(2+) signaling, oxidative stress, and cellular viability by presenilins within the context of AD and discuss the relevance of presenilins in AD drug development efforts.
format Online
Article
Text
id pubmed-6032171
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-60321712018-07-13 Presenilins as Drug Targets for Alzheimer’s Disease—Recent Insights from Cell Biology and Electrophysiology as Novel Opportunities in Drug Development Duncan, R. Scott Song, Bob Koulen, Peter Int J Mol Sci Review A major cause underlying familial Alzheimer’s disease (AD) are mutations in presenilin proteins, presenilin 1 (PS1) and presenilin 2 (PS2). Presenilins are components of the γ-secretase complex which, when mutated, can affect amyloid precursor protein (APP) processing to toxic forms of amyloid beta (Aβ). Consequently, presenilins have been the target of numerous and varied research efforts to develop therapeutic strategies for AD. The presenilin 1 gene harbors the largest number of AD-causing mutations resulting in the late onset familial form of AD. As a result, the majority of efforts for drug development focused on PS1 and Aβ. Soon after the discovery of the major involvement of PS1 and PS2 in γ-secretase activity, it became clear that neuronal signaling, particularly calcium ion (Ca(2+)) signaling, is regulated by presenilins and impacted by mutations in presenilin genes. Intracellular Ca(2+) signaling not only controls the activity of neurons, but also gene expression patterns, structural functionality of the cytoskeleton, synaptic connectivity and viability. Here, we will briefly review the role of presenilins in γ-secretase activity, then focus on the regulation of Ca(2+) signaling, oxidative stress, and cellular viability by presenilins within the context of AD and discuss the relevance of presenilins in AD drug development efforts. MDPI 2018-05-31 /pmc/articles/PMC6032171/ /pubmed/29857474 http://dx.doi.org/10.3390/ijms19061621 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Duncan, R. Scott
Song, Bob
Koulen, Peter
Presenilins as Drug Targets for Alzheimer’s Disease—Recent Insights from Cell Biology and Electrophysiology as Novel Opportunities in Drug Development
title Presenilins as Drug Targets for Alzheimer’s Disease—Recent Insights from Cell Biology and Electrophysiology as Novel Opportunities in Drug Development
title_full Presenilins as Drug Targets for Alzheimer’s Disease—Recent Insights from Cell Biology and Electrophysiology as Novel Opportunities in Drug Development
title_fullStr Presenilins as Drug Targets for Alzheimer’s Disease—Recent Insights from Cell Biology and Electrophysiology as Novel Opportunities in Drug Development
title_full_unstemmed Presenilins as Drug Targets for Alzheimer’s Disease—Recent Insights from Cell Biology and Electrophysiology as Novel Opportunities in Drug Development
title_short Presenilins as Drug Targets for Alzheimer’s Disease—Recent Insights from Cell Biology and Electrophysiology as Novel Opportunities in Drug Development
title_sort presenilins as drug targets for alzheimer’s disease—recent insights from cell biology and electrophysiology as novel opportunities in drug development
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032171/
https://www.ncbi.nlm.nih.gov/pubmed/29857474
http://dx.doi.org/10.3390/ijms19061621
work_keys_str_mv AT duncanrscott presenilinsasdrugtargetsforalzheimersdiseaserecentinsightsfromcellbiologyandelectrophysiologyasnovelopportunitiesindrugdevelopment
AT songbob presenilinsasdrugtargetsforalzheimersdiseaserecentinsightsfromcellbiologyandelectrophysiologyasnovelopportunitiesindrugdevelopment
AT koulenpeter presenilinsasdrugtargetsforalzheimersdiseaserecentinsightsfromcellbiologyandelectrophysiologyasnovelopportunitiesindrugdevelopment